drug issues
S0212: Phase IIb Randomized Study of Celecoxib in Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix
Sponsor study identifier
Secondary identifiers
OTHER · SWOG
NIH
interventional
0
0 countries
N/A
Study Start
Not reported
Date not reportedPrimary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedRATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Celecoxib may be effective in preventing cervical cancer. PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing cervical cancer in patients who have high-grade squamous intraepithelial lesions of the cervix.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 4, 2003
Actual (reported)November 5, 2003
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
William R. Robinson, MD
Harrington Cancer Center
0 participants (actual enrollment reported by the registry).
First Submitted
November 4, 2003
First Posted
November 5, 2003
Last Updated
November 8, 2013
Record last verified: 2013-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.